ABC | Volume 114, Nº2, Fevereiro 2020

Atualização Atualização da Diretriz Brasileira de Cardiologia Nuclear – 2020 Arq Bras Cardiol. 2020; 114(2):325-429 411. Bensimhon L, Lavergne T, Hugonnet F, Mainardi JL, Latremouille C, Maunoury C, et al. Whole body [(18) F] fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: a preliminary prospective study. Clin Microbiol Infect. 2011;17(6):836-44. 412. Yeh CL, Liou JY, Chen SW, Chen YK. Infective endocarditis detected by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in a patient with occult infection. Kaohsiung J Med Sci. 2011;27(11):528-31. 413. Kim J, Feller ED, Chen W, Dilsizian V. FDG PET/CT imaging for LVAD associated infections. JACC Cardiovasc Imaging. 2014;7(8):839–42. 414. Litzler PY, Manrique A, Etienne M, Salles A, Edet-Sanson A, Vera P, et al. Leukocyte SPECT/CT for detecting infection of left-ventricular-assist devices: preliminary results. J Nucl Med. 2010;51(7):1044-8. 415. Dell'Aquila AM, Mastrobuoni S, Alles S,Wenning C, HenrykW, Schneider SR, et al. Contributory role of fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis and clinical management of infections in patients supported with a continuous-flow left ventricular assist device. Ann Thorac Surg. 2016;101(1):87-94. 416. Tlili G, Amraoui S, MesguichC, Rivière A, Bordachar P, Hindié E, et al. High performances of (18)F-fluorodeoxyglucose PET-CT in cardiac implantable device infections:astudyof40patients.JNuclCardiol. 2015;22(4):787-98. 417. Amraoui S, Tlili G, Sohal M, Berte B, Hindié E, Ritter P, et al. Contribution of PET imaging to the diagnosis of septic embolism in patients with pacing lead endocarditis. JACC Cardiovasc Imaging. 2016;9(3):283-90. 418. SimonenP,Lehtonen J,KandolinR,Schildt J,MarjasuoS,MiettinenH,etal. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol. 2015;116(10):1581-5. 419. Piriou N, Sassier J, Pallardy A, Serfaty JM, Trochu JN. Utility of cardiac FDG-PET imaging coupled to magnetic resonance for the management of an acutemyocarditis with non-informative endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16(5):574. 420. Cooper LT, Baughman KL, Feldman AM, Frustaci A, JessupM, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2007;28(24):3076-93. 421. Friedrich MG, Marcotte F. Cardiac magnetic resonance assessment of myocarditis. Circ Cardiovasc Imaging. 2013;6(5):833-9. 422. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al; International Consensus Group on Cardiovascular MagneticResonance inMyocarditis.Cardiovascularmagneticresonance in m yocarditis:AJACCWhitePaper.JAmCollCardiol. 2009;53(17):1475-87. 423. Lurz P, Eitel I, Adam J, Steiner J, Grothoff M, Desch S, et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging. 2012;5(5):513-24. 424. Ozawa K, Funabashi N, Daimon M, Takaoka H, Takano H, Uehara M, et al. Determination of optimumperiods between onset of suspected acute myocarditisand (1)(8)F-fluorodeoxyglucosepositronemissiontomography in the diagnosis of inflammatory left ventricular myocardium. Int J Cardiol. 2013;169(3):196-200. 425. von Olshausen G, Hyafil F, Langwieser N, Laugwitz KL, Schwaiger M2, Ibrahim T. Detection of acute inflammatory myocarditis in Epstein Barr virus infection using hybrid 18F-fluoro-deoxyglucose-positron emission tomography/magnetic resonance imaging. Circulation. 2014;130(11):925-6. 426. Nensa F, Kloth J, Tezgah E, Poeppel TD, Heusch P, Goebel J, et al. Feasibility of FDG-PET inmyocarditis: comparison toCMR using integrated PET/MRI. J Nucl Cardiol. 2018;25(3):785-94. 427. Takano H, Nakagawa K, Ishio N, Daimon M, Daimon M, Kobayashi Y, et al. Active myocarditis in a patient with chronic active Epstein-Barr virus infection. Int J Cardiol. 2008;130(1):e11-3. 428. Nensa F, Poeppel TD, Beiderwellen K, Schelhorn J, Mahabadi AA, Erbel R, et al. Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology. 2013;268(2):366-73. 429. Nensa F, Poeppel TD, Krings P, Schlosser T. Multiparametric assessment of myocarditis using simultaneous positron emission tomography/magnetic resonance imaging. Eur Heart J. 2014;35(32):2173. 430. Alter P, Figiel JH, Rupp TP, Bachmann GF, Maisch B, Rominger MB. MR, CT, and PET imaging in pericardial disease. Heart Fail Rev. 2013;18(3):289–306. 431. LosikSB,StudentsovaY,MargouleffD.Chemotherapy-inducedpericarditis on F-18 FDG positron emission tomography scan. Clin Nucl Med. 2003;28(11):913-5. 432. Salomäki SP, Hohenthal U, Kemppainen J, Pirilä L, Saraste A. Visualization of pericarditis by fluorodeoxyglucose PET. Eur Heart J Cardiovasc Imaging. 2014;15(3):291. 433. Shao D, Wang SX, Liang CH, Gao Q. Differentiation of malignant from benign heart and pericardial lesions using positron emission tomography and computed tomography. J Nucl Cardiol. 2011;18(4):668-77. 434. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885-9. 435. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426-35. 436. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120(20):1969-77. 437. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med. 1996;100(4):423-7. 438. Cooper LT, Baughman KL, Feldman AM, Frustaci A, JessupM, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2007;28(24):3076-93. 439. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metanalysis including the Ontario experience. J Nucl Med. 2012;53(2):241-8. 440. Tang R, Wang JT, Wang L, Le K, Huang Y, Hickey AJ, et al. Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Clin Nucl Med. 2016;41(7): e327-39. 441. McArdle B, Dowsley TF, Cocker MS, Ohira H, deKemp RA, DaSilva J, et al. Cardiac PET: metabolic and functional imaging of themyocardium. Semin Nucl Med. 2013;43(6):434-48. 442. Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med. 2014;55(1):99-106. 443. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63(4):329-36. 444. Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016;6(1):50-63. 428